Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
Saturday, June 5, 2010 - 10:10
in Health & Medicine
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas MD Anderson Cancer Centre...